৳ ০.০০
আপনার সব স্বাস্থ্যসেবার সমাধান — এখন এক জায়গাতেই
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬
৳ ০.০০
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬


Quantity:
Products
Payment
Delivery
Generic name: Tirzepatide
Formulation: 7.5 mg/0.5 ml pre-filled syringe (subcutaneous injection)
Manufacturer: Incepta Pharmaceuticals Ltd., Bangladesh
Therapeutic class: GLP-1 receptor agonist (also acts on GIP receptors)
Tirzepatide is a dual GIP and GLP-1 receptor agonist.
It enhances insulin secretion and reduces glucagon levels in a glucose-dependent manner.
The drug has a long half-life (~5 days) due to albumin binding, allowing once-weekly dosing.
Approved use: Type 2 diabetes mellitus (as an adjunct to diet and exercise).
Not indicated for: Type 1 diabetes or patients with a history of pancreatitis.
Starting dose: 2.5 mg once weekly (not for glycemic control, only initiation).
Titration: Increase to 5 mg after 4 weeks; further increments of 2.5 mg every ≥4 weeks if needed.
Maximum dose: 15 mg once weekly.
Administration: Subcutaneous injection in abdomen, thigh, or upper arm. Rotate injection sites.
Missed dose: Take within 4 days; otherwise skip and continue regular schedule.
Contraindicated in:
Patients with hypersensitivity to tirzepatide.
Personal/family history of medullary thyroid carcinoma (MTC) or MEN 2 syndrome.
Precautions:
Monitor for pancreatitis symptoms.
Risk of hypoglycemia when combined with insulin or sulfonylureas.
May delay gastric emptying → affects absorption of oral drugs (e.g., warfarin, contraceptives).
Monitor renal function in patients with impairment.
Watch for progression of diabetic retinopathy and gallbladder disease.
Common: Nausea, diarrhea, decreased appetite, vomiting, constipation, abdominal pain.
Serious risks: Thyroid tumors, pancreatitis, gallbladder disease, hypersensitivity reactions.
Pregnancy: Use only if benefits outweigh risks.
Breastfeeding: Consider maternal need vs. potential infant risk.
Children/adolescents (<18 years): Safety not established.
Store in a refrigerator (2°C–8°C).
Do not freeze. Protect from light.
Keep out of reach of children.


Tirzepatide is an injectable medication used for type 2 diabetes management and, in many cases, weight management. It works as a dual agonist of GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors, helping regulate blood sugar and appetite.
Tirzepatide helps lower blood glucose levels, improve insulin sensitivity, reduce appetite, and support significant weight loss. It may also reduce cardiovascular risk factors in patients with type 2 diabetes.





